



## Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

March 25, 2024 8:30 PM EDT

CELEBRATION, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- **Zevra Therapeutics, Inc. (NasdaqGS: ZVRA)** (Zevra or the Company), a rare disease therapeutics company, today announced that it will participate in the upcoming 23<sup>rd</sup> Annual Needham Virtual Healthcare Conference being held virtually on April 8-9, 2024. The Company's presentation will take place on Monday, April 8, 2024, at 3:45 p.m. ET. Additionally, members of Zevra's management team will be available for one-on-one investor meetings with registered attendees throughout the conference.

The live webcast will be available [here](#). Following Zevra's presentation, the archived presentation will be accessible under "Events & Presentations" on the Investor Relations section of Zevra's website at [investors.zevra.com](https://investors.zevra.com). To register for the conference, contact your Needham Sales Representative.

### About Zevra Therapeutics:

Zevra Therapeutics is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.

For more information, please visit [www.zevra.com](https://www.zevra.com) or follow us on [X](#) (formerly Twitter) and [LinkedIn](#).

### Cautionary Note Concerning Forward-Looking Statements:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra's participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra's Annual Report on Form 10-K for the year ended December 31, 2022, as updated in Zevra's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

### Zevra Contacts:

Nichol Ochsner  
+1 (732) 754-2545  
[nochsner@zevra.com](mailto:nochsner@zevra.com)

### Russo Partners Contacts:

David Schull  
+1 (858) 717-2310  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

Ignacio Guerrero-Ros, Ph.D.  
+1 (646) 942-5604  
[ignacio.guerrero-ros@russopartnersllc.com](mailto:ignacio.guerrero-ros@russopartnersllc.com)

